Literature DB >> 15309731

Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.

Yun-Lin Wu1, Jing Ye, Shu Zhang, Jie Zhong, Rong-Ping Xi.   

Abstract

AIM: To investigate the relationship between insulin-like growth factor-I, -II (IGF-I and IGF-II), IGF-binding protein 3 (IGFBP-3) and Child-Pugh score in patients with liver cirrhosis, and to search for potential clinical markers of liver function.
METHODS: Forty-four patients with advanced liver cirrhosis of viral origin were divided into 3 groups according to severity of cirrhosis (Child-Pugh score) and 38 healthy subjects served as controls. Serum levels of IGF-I, IGF-II and IGFBP-3 were measured by immunoradiometric assay.
RESULTS: Serum IGF-I, IGF-II and IGFBP-3 levels were significantly lower in patients with cirrhosis than in controls, and serum concentrations of IGF-I, IGF-II and IGFBP-3 were associated with the severity of liver dysfunction, and dropped sharply during the progression of liver failure. Among these 3 parameters, serum IGF-II was the most sensitive and effective indicator for liver dysfunction. Concentrations of IGF-I <30 ng/mL, IGF-II <200 ng/mL and IGFBP-3 <6 ng/mL implied a negative prognosis for patients with liver cirrhosis.
CONCLUSION: Serum IGF-I, IGF-II and IGFBP-3 may provide a new dimension in the assessment of liver dysfunction. Combined detection of serum IGF-I, IGF-II and IGFBP-3 with Child-Pugh score is more effective in predicting prognosis than Child-Pugh score alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309731      PMCID: PMC4572205          DOI: 10.3748/wjg.v10.i18.2740

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis.

Authors:  Z R Fan; D H Yang; J Cui; H R Qin; C C Huang
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.

Authors:  Gherardo Mazziotti; Francesca Sorvillo; Filomena Morisco; Antonella Carbone; Mario Rotondi; Gianfranca Stornaiuolo; Davide F Precone; Michele Cioffi; Giovanni B Gaeta; Nicola Caporaso; Carlo Carella
Journal:  Cancer       Date:  2002-12-15       Impact factor: 6.860

3.  Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis.

Authors:  L Caregaro; F Alberino; P Amodio; C Merkel; P Angeli; M Plebani; M Bolognesi; A Gatta
Journal:  Nutrition       Date:  1997-03       Impact factor: 4.008

4.  Effect of IGF-I on total serum antioxidant status in cirrhotic rats.

Authors:  M García-Fernández; I Castilla-Cortázar; M Díaz-Sánchez; F Díez Caballero; A Castilla; A Díaz Casares; I Varela-Nieto; S González-Barón
Journal:  J Physiol Biochem       Date:  2003-06       Impact factor: 4.158

5.  Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy.

Authors:  T Inaba; H Saito; T Inoue; I Han; S Furukawa; T Matsuda; S Ikeda; T Muto
Journal:  J Hepatol       Date:  1999-08       Impact factor: 25.083

6.  Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis.

Authors:  Anthony J Donaghy; Patric J D Delhanty; Ken K Ho; Roger Williams; Robert C Baxter
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

7.  Reactivity of IGF binding protein-3 isoforms towards concanavalin A in healthy adults and subjects with cirrhosis.

Authors:  Olgica Nedić; Judith Anna Nikolić; Sladana Prisić; Jelena Acimovic; Ljiljana hajdukovic-Dragojlovic
Journal:  Addict Biol       Date:  2003-03       Impact factor: 4.280

8.  Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis.

Authors:  T Vyzantiadis; S Theodoridou; O Giouleme; P Harsoulis; N Evgenidis; A Vyzantiadis
Journal:  Hepatogastroenterology       Date:  2003 May-Jun

9.  Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis.

Authors:  S Møller; A Juul; U Becker; A Flyvbjerg; N E Skakkebaek; J H Henriksen
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

10.  Expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor and its intervention by interleukin-10 in experimental hepatic fibrosis.

Authors:  Xiao-Zhong Wang; Zhi-Xin Chen; Li-Juan Zhang; Yun-Xin Chen; Dan Li; Feng-Lin Chen; Yue-Hong Huang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

View more
  16 in total

1.  Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools.

Authors:  Emelyne Dejeux; Virginie Audard; Catherine Cavard; Ivo Glynne Gut; Benoit Terris; Jörg Tost
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

2.  Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases.

Authors:  Karam A Mahdy; Hanaa H Ahmed; Fathia Mannaa; Azza Abdel-Shaheed
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

3.  Characteristics of adult patients with growth hormone deficiency who underwent neurosurgery for functioning and non-functioning pituitary adenomas and craniopharyngiomas.

Authors:  R Baldelli; A Bianchi; F Diacono; M Passeri; A Fusco; D Valle; M Poggi; M Terlini; V Toscano; G Tamburrano; A Pontecorvi; G Maira; L De Marinis
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

4.  Serum prolidase and IGF-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats.

Authors:  Orhan Tarçin; Nursal Gedik; Berna Karakoyun; Veysel Tahan; Gagan Sood; Ciğdem Celikel; Nurdan Tözün
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

Review 5.  Predictive factors of short term outcome after liver transplantation: A review.

Authors:  Giuliano Bolondi; Federico Mocchegiani; Roberto Montalti; Daniele Nicolini; Marco Vivarelli; Lesley De Pietri
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

6.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

7.  Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis.

Authors:  Carina Gabriela Correa; Bruno da Silveira Colombo; Marcelo Fernando Ronsoni; Pedro Eduardo Soares E Silva; Leonardo Fayad; Telma Erotides Silva; Letícia Muraro Wildner; Maria Luiza Bazzo; Esther Buzaglo Dantas-Correa; Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  World J Hepatol       Date:  2016-06-18

8.  Postoperative Insulin-Like Growth Factor 1 Levels Reflect the Graft's Function and Predict Survival after Liver Transplantation.

Authors:  Daniele Nicolini; Federico Mocchegiani; Gioia Palmonella; Martina Coletta; Marina Brugia; Roberto Montalti; Giammarco Fava; Augusto Taccaliti; Andrea Risaliti; Marco Vivarelli
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

9.  A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis.

Authors:  Asghar Khoshnood; Mohsen Nasiri Toosi; Mohammad Jafar Faravash; Alireza Esteghamati; Hosein Froutan; Hadi Ghofrani; Mohammad Kalani; Arash Miroliaee; Ahmad Abdollahi; Andrabi Yasir
Journal:  Hepat Mon       Date:  2013-02-23       Impact factor: 0.660

10.  Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C.

Authors:  Agnieszka Adamek; Aldona Kasprzak; Agnieszka Seraszek; Hanna Mikoś; Aleksandra Bura; Iwona Mozer-Lisewska
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.